Masters Programme Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium
ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training Consortium has endorsed the Masters in International Clinical Research and Technology for clinical research professionals.
The Asia Training Consortium (ATC) was founded in 2012 as a unified platform for pharmaceutical companies to establish common goals and share resources to provide world-class training and development in clinical research in Asia. It is currently a consortium of 17 companies, including large top 20 pharmaceutical companies such as Merck, Novartis, Pfizer, Astellas and AstraZeneca, global CROs and training institutions including Edinburgh Napier University. This is the first endorsement from ATC of an academic qualification to meet the needs for further qualifications for research professionals.
The Masters in International Clinical Research and Technology was launched last year between Edinburgh Napier University and ClinTec International to support the development of clinical research staff throughout the world and has now been endorsed by the ATC. This innovative Masters programme is an exciting collaboration, which builds upon the clinical research and educational expertise that exists within these two organisations. The Masters programme is accessible globally and has enrolled students from 14 countries, including students based in UAE, Lebanon, South Africa, India and the Philippines, as well as from France, Austria, Sweden, UK, Czech Republic, Slovenia, Lithuania, Croatia and Romania. This successful innovative industry/academic collaboration leading to a Masters Degree led to ClinTec being awarded the Microsoft Innovation of the Year Award 2014 at the UK’s largest Business Award Ceremony, with guest speaker global entrepreneur, Sir Richard Branson. Over the last 5 years, ClinTec and Edinburgh Napier University have delivered clinical research courses to over 1000 clinical professionals globally, with over 200 based in Asia.
ClinTec International is a global CRO, with a presence in over 50 countries across 5 continents. On the occasion of the endorsement of the Masters programme by ATC, Dr Rabinder Buttar, Founder, Chairman and CEO of ClinTec International, commented: “ClinTec International is delighted to receive this endorsement from the Asia Training Consortium. As ClinTec has a global presence in over 50 countries, we are very pleased to be associated with a platform that provides world-class training and development in Asia”.
Professor Andrea Nolan, Principal and Vice-Chancellor of Edinburgh Napier University stated: “At Edinburgh Napier University we have a history of collaborating with industry to give students the best possible education to equip them to become leaders in their field. We are delighted to have the endorsement from the Asia Training Consortium who share the joint aspirations of providing world class training for clinical research professionals”.
John Constantine, Chair, Asia Training Consortium, said: “This is yet another example of collaboration within and across industries to further quality and excellence in clinical research. ATC membership is excited to have this endorsement between a respected University, Edinburgh Napier University, and ClinTec, one of the premier contract research organizations. I look forward to further collaborations like this between ATC members in the future.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance